This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.
TheInstitute also recommends Allergan's Ozurdex in final guidance. Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema ... Meanwhile, NICE also recommended the use of Allergan's
The preliminary recommendations cite the implant, marketed by Allergan as Ozurdex, as a treatment option in patients where the implant is to be used in an eye with an intraocular (pseudophakic) ... Ozurdex is injected into the eye once every six months
Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).
The European Commission granted marketing authorisation to Ozurdex, an eye implant that contains the corticosteroid dexamethasone, as a treatment for adults with visual impairment due to diabetic macular oedema (DMO). ... Ozurdex joins a competitive
On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have
Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...